List of Excipients in Branded Drug CYRAMZA

CYRAMZA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

CYRAMZA (ramucirumab) is a recombinant human IgG1 monoclonal antibody supplied as a sterile intravenous concentrate. Its commercial formulation uses a conventional antibody excipient system: histidine buffer, sodium chloride, glycine, polysorbate 80, and water for injection. The strongest opportunities are in excipient quality, oxidation and aggregation control, infusion-ready presentations, biosimilar formulation platforms, and manufacturing services rather than in a novel small-molecule excipient claim.

What excipients are used in CYRAMZA?

CYRAMZA is supplied as a 10 mg/mL solution in single-dose vials containing 100 mg/10 mL or 500 mg/50 mL of ramucirumab. The formulation contains histidine, histidine hydrochloride monohydrate, sodium chloride, glycine, polysorbate 80, and water for injection.[1]

Formulation component	Function	Commercial relevance
Histidine and histidine hydrochloride monohydrate	Buffer system	Controls pH during storage and administration
Sodium chloride	Tonicity adjustment	Supports intravenous compatibility
Glycine	Stabilizer and tonicity contributor	Helps control protein self-association and formulation stress
Polysorbate 80	Surfactant	Reduces interfacial adsorption and agitation-induced aggregation
Water for injection	Vehicle	Sterile parenteral solvent

CYRAMZA is diluted before administration in 0.9% sodium chloride injection. The FDA label specifies a final concentration of 1 to 15 mg/mL and instructs users to avoid dextrose-containing solutions. The diluted product is administered by intravenous infusion over approximately 60 minutes, although the infusion duration may be reduced to 30 minutes if the first infusion is tolerated.[1]

The excipient system is not unusual for an antibody product, but it creates demanding quality requirements. The commercial value lies in maintaining protein integrity through manufacturing, storage, transport, dilution, and infusion.

How does CYRAMZA’s formulation affect excipient strategy?

The primary technical risks are aggregation, fragmentation, oxidation, subvisible particles, adsorption to process surfaces, and loss of potency. Each excipient addresses part of that risk profile.

Histidine buffer

Histidine is widely used in monoclonal antibody formulations because it provides buffering near mildly acidic pH and generally has a lower reactivity profile than some alternative buffers. For ramucirumab, the buffer must preserve the antibody’s structure without increasing deamidation, aggregation, or charge-variant formation during long-term storage.

Commercial opportunities include:

• High-purity, low-bioburden histidine and histidine hydrochloride
• Pharmaceutical-grade buffer concentrates
• Single-use buffer preparation systems
• In-line pH and conductivity monitoring
• Formulation screening services for ramucirumab biosimilars

A supplier competing on price alone will face limited differentiation. More defensible positioning requires documented control of trace metals, endotoxin, bioburden, particulate load, and lot-to-lot pH performance.

Sodium chloride

Sodium chloride primarily supports isotonicity and intravenous tolerability. It is a low-cost component, so the opportunity is not the molecule itself. Value comes from parenteral-grade manufacturing, validated supply, sterile processing, and compatibility with closed-system compounding.

For hospitals, the more commercially relevant question is whether ramucirumab dilution can be integrated into ready-to-administer products without introducing additional hold-time, particulate, or adsorption risks.

Glycine

Glycine can contribute to stabilization and tonicity. Its role is formulation-dependent and must be assessed with the antibody, buffer, surfactant, container closure, and storage temperature.

Potential commercial applications include:

• Glycine-containing antibody formulation libraries
• Excipient compatibility studies
• Freeze-thaw stabilization
• Low-temperature transport protection
• Development of higher-concentration ramucizumab or biosimilar presentations

Glycine is a commodity excipient. Its strategic value increases when combined with proprietary formulation screening, analytical characterization, or process-development data.

Polysorbate 80

Polysorbate 80 is the most technically sensitive excipient in the CYRAMZA formulation. It limits adsorption at air-liquid and solid-liquid interfaces, but it can undergo hydrolysis and oxidation. Degradation may generate free fatty acids, peroxide species, particles, or other impurities that affect antibody stability.

This creates the clearest excipient opportunity in the CYRAMZA supply chain.

Commercial offerings may include:

• Low-peroxide polysorbate 80
• Low-particulate and low-free-fatty-acid grades
• Controlled fatty-acid distribution
• Stabilized or highly purified polysorbate 80
• Oxidation monitoring methods
• Excipient lot-release testing
• Container and tubing compatibility studies
• Alternative surfactant screening for biosimilar products

Any alternative surfactant must demonstrate equivalent or superior protection against adsorption and aggregation without creating new risks involving immunogenicity, extractables, leachables, subvisible particles, or regulatory qualification.

What formulations are protected by CYRAMZA-related intellectual property?

CYRAMZA is a biologic, so its exclusivity profile differs from that of a conventional small-molecule drug. Product and formulation protection may arise from several patent categories:

1. Ramucirumab composition-of-matter claims.
2. Antibody sequence and variable-region claims.
3. Binding-site or epitope claims.
4. Methods of treating oncology indications.
5. Dosing and administration regimens.
6. Cell-culture and manufacturing methods.
7. Purification processes.
8. Stable liquid formulations.
9. Container-closure and delivery presentations.

The commercial formulation itself may be covered by formulation or manufacturing patents, but the presence of a particular excipient in the FDA label does not establish patent protection. Patent scope must be assessed claim by claim against issued patents, continuations, terminal disclaimers, prosecution history, and expiration adjustments.

For excipient companies, the more practical issue is freedom to operate around alternative formulations. A biosimilar developer may avoid a formulation claim by changing the buffer, surfactant, concentration, container, or storage presentation, provided the resulting product satisfies comparability and regulatory requirements.

When does CYRAMZA lose exclusivity?

CYRAMZA received FDA approval on April 21, 2014, under BLA 125477.[2] As a reference biologic, it receives 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act, subject to the statutory framework and any applicable pediatric extension. The base period therefore reaches April 21, 2026.[3]

That date does not guarantee immediate biosimilar launch. Market entry also depends on:

• Biosimilar approval timing
• Patent litigation
• Patent settlement terms
• Commercial launch decisions
• Manufacturing readiness
• Interchangeability strategy
• State substitution rules
• Contracting with oncology providers and payers

The relevant U.S. pathway is the 351(k) biosimilar pathway, not an ANDA pathway. CYRAMZA is listed in the FDA Purple Book as a licensed biological product. It is not managed through the small-molecule Orange Book framework in the same way as a conventional tablet or capsule.[4]

What is the Orange Book and Purple Book status of CYRAMZA?

CYRAMZA is a biologic approved under a BLA rather than an NDA. The Purple Book is therefore the principal FDA reference for the product’s biological-product status and biosimilar-related information.[4]

Regulatory issue	CYRAMZA position
Active ingredient	Ramucirumab
Product type	Recombinant monoclonal antibody
FDA pathway	BLA 125477
Administration	Intravenous infusion
Orange Book role	Limited; not the principal biologic listing system
Purple Book relevance	Reference-product and biosimilar status
Biosimilar pathway	Section 351(k)
Reference approval date	April 21, 2014
Base 12-year reference exclusivity endpoint	April 21, 2026

Patent certifications associated with ANDA Paragraph IV litigation are not the primary mechanism for challenging CYRAMZA. A biosimilar sponsor instead follows the patent-information exchange and litigation procedures under the BPCIA, often called the “patent dance.” A biosimilar may also proceed under a strategy that limits information exchange or delays commercial launch while patent disputes continue.

Which companies are challenging CYRAMZA exclusivity?

The commercial threat is expected to come from biosimilar developers and large biologics manufacturers rather than conventional generic-drug companies. Potential competitors include companies with established oncology and monoclonal-antibody capabilities, such as Amgen, Biocon Biologics, Celltrion, Samsung Bioepis, Sandoz, Fresenius Kabi, and other regional developers.

Publicly available information should be checked before attributing a specific CYRAMZA biosimilar filing, patent suit, or settlement to any company. A product can be under development without appearing in a public litigation docket, and a company may conduct clinical, analytical, or manufacturing work before announcing a commercial program.

The practical competitive indicators are:

• FDA acceptance of a 351(k) application
• Publicly disclosed phase 3 or comparative clinical studies
• Manufacturing-site inspection activity
• Purple Book listing
• Patent litigation filings
• Formulary contracting announcements
• Regional approval in Europe or other major markets

What generic entry risks exist for CYRAMZA?

CYRAMZA faces biosimilar erosion rather than traditional generic substitution. The main risks are price competition, formulary exclusion, oncology-practice substitution, and contracting pressure.

A biosimilar does not need to reproduce every commercial attribute of CYRAMZA. It must demonstrate high similarity and no clinically meaningful differences in safety, purity, and potency. This leaves room for differences in:

• Buffer composition
• Surfactant grade
• Excipient concentration
• Vial configuration
• Dilution instructions
• Shelf life
• Infusion preparation
• Device or administration presentation

A biosimilar with a more robust formulation could compete on reduced aggregation, longer in-use stability, easier handling, or a ready-to-administer format. Those attributes may be more commercially valuable than a small reduction in excipient cost.

How strong is the CYRAMZA patent estate?

CYRAMZA’s defensibility is likely strongest around the antibody itself, regulatory exclusivity, clinical positioning, and manufacturing know-how. Formulation patents can delay or complicate entry, but they are typically more vulnerable to design-around strategies than composition-of-matter claims.

Protection layer	Relative commercial importance	Design-around potential
Antibody sequence and composition	High	Low
Regulatory reference-product exclusivity	High but time-limited	None during statutory period
Method-of-use claims	Medium to high	Moderate
Dosing-regimen claims	Medium	Moderate to high
Liquid formulation claims	Medium	Moderate
Manufacturing process claims	Medium	Moderate
Excipient-specific claims	Low to medium	High
Container or presentation claims	Low to medium	High

The most important diligence question is whether relevant formulation claims require a specific combination of histidine, glycine, sodium chloride, and polysorbate 80, or whether they cover broader concentration and pH ranges. Broad claims can constrain biosimilar development. Narrow claims can often be avoided through a modified buffer, surfactant, or presentation.

What excipient opportunities exist for CYRAMZA suppliers?

High-purity polysorbate 80

This is the strongest opportunity. Suppliers can differentiate through peroxide control, hydrolysis resistance, particle reduction, analytical transparency, and improved consistency across lots.

Formulation development for biosimilars

Biosimilar developers need formulation systems that achieve comparable stability without copying every reference-product attribute. Contract development organizations can provide:

• Design-of-experiment formulation screening
• Forced-degradation studies
• Subvisible-particle analysis
• Polysorbate degradation profiling
• Freeze-thaw and agitation studies
• Container-closure compatibility
• Dilution and infusion-bag studies

Ready-to-administer presentations

CYRAMZA is a concentrate that requires dilution. A supplier or drug-product developer could pursue a ready-to-use bag, prefilled infusion container, or other hospital workflow product. The commercial case depends on stability after dilution, aseptic processing, transport, reimbursement, and compatibility with oncology pharmacy systems.

Extended in-use stability

The FDA label places specific limits on storage and use after dilution.[1] A formulation or presentation that supports longer validated in-use stability could reduce pharmacy waste and improve scheduling flexibility. The product would require robust data on potency, aggregates, particles, sterility, and container compatibility.

Alternative surfactants

Poloxamer 188 and other surfactant systems may be evaluated in a biosimilar formulation. The regulatory burden is higher than simply changing a buffer because surfactant identity can affect product quality, immunogenicity risk, and comparability. A successful alternative must produce a clear performance or supply-chain advantage.

What manufacturing and IP barriers affect commercial entry?

Manufacturing is a major barrier because ramucirumab is a complex glycoprotein produced in mammalian cell culture. A competitor must establish control over:

• Cell line and expression system
• Upstream process parameters
• Glycosylation profile
• Protein-A and polishing steps
• Viral clearance
• Aggregation and fragmentation
• Sterile filtration
• Filling and container closure
• Long-term stability

Excipient selection interacts with every stage. Polysorbate can be introduced during formulation, but trace impurities and process residues may affect stability. Histidine and glycine require control of concentration and pH at commercial scale. The final product must remain compatible with vial components, transfer devices, infusion bags, and administration tubing.

The most defensible commercial IP may therefore involve an integrated formulation and process package rather than a single excipient claim.

How does CYRAMZA compare with competing oncology antibodies?

CYRAMZA competes in oncology markets with other biologics that use similar formulation principles, including bevacizumab, trastuzumab, pertuzumab, pembrolizumab, nivolumab, and cetuximab. Most use a buffer, tonicity agent, stabilizer, and surfactant, but their exact pH, concentration, container, and storage profiles differ.

Product type	Common formulation issue	Opportunity relative to CYRAMZA
Anti-VEGF antibodies	Aggregation and particle control	Shared polysorbate and container expertise
Checkpoint inhibitors	Long-term stability and oxidation	Shared high-purity surfactant platform
HER2 antibodies	High-volume oncology use	Scale advantage for excipient suppliers
Biosimilar antibodies	Comparability and design-around	Demand for formulation screening
Infusion products	Preparation time and waste	Ready-to-administer systems

CYRAMZA is commercially attractive as part of a broader antibody-excipient platform. A supplier that qualifies materials for multiple oncology antibodies can spread regulatory, analytical, and manufacturing investment across a larger customer base.

What is the revenue exposure to CYRAMZA erosion?

CYRAMZA generates revenue across multiple indications, including non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, and hepatocellular carcinoma, depending on jurisdiction and label.[1] Sales exposure is concentrated in hospital and oncology channels, where contracting and treatment protocols can accelerate biosimilar uptake.

The commercial impact of biosimilar entry will depend on:

• Share of CYRAMZA sales from indications with strong treatment alternatives
• Payer formulary positioning
• Provider reimbursement economics
• Availability of interchangeability designation
• Biosimilar discounts
• Eli Lilly’s contracting strategy
• Physician sensitivity to formulation and administration differences

Excipient suppliers have lower direct revenue exposure than the originator but may benefit from increased demand for biosimilar development, clinical comparability, commercial-scale manufacturing, and post-approval lifecycle products.

What patent litigation affects CYRAMZA?

CYRAMZA-related litigation should be evaluated through federal court dockets, USPTO records, FDA biologic listings, and company disclosures. The legally relevant disputes may involve antibody patents, formulation patents, manufacturing methods, dosing claims, or biosimilar BPCIA procedures.

A commercial diligence review should distinguish among:

• Issued patents versus pending applications
• Patents listed or referenced in biologic patent disclosures
• Inter partes review or post-grant proceedings
• Declaratory-judgment actions
• BPCIA patent litigation
• Settlement agreements
• License agreements
• Patent expiry dates by jurisdiction

No single patent date determines market entry. A biosimilar may launch after regulatory approval if the sponsor believes remaining patents do not block launch, if it reaches a settlement, or if it accepts litigation risk.

Key Takeaways

• CYRAMZA uses histidine, histidine hydrochloride, sodium chloride, glycine, polysorbate 80, and water for injection.
• Polysorbate 80 quality, oxidation control, and particle management present the strongest excipient opportunity.
• CYRAMZA is a BLA biologic, so Purple Book and BPCIA analysis are more relevant than conventional Orange Book Paragraph IV analysis.
• The base 12-year U.S. reference-product exclusivity period reaches April 21, 2026.
• Biosimilar developers can potentially differentiate through surfactant quality, in-use stability, ready-to-administer formats, and hospital workflow.
• Formulation patents may create barriers, but alternative buffers, surfactants, concentrations, and presentations can provide design-around options.
• The most valuable commercial position is an integrated excipient, analytical, and formulation-development platform for oncology antibodies.

FAQs

Can CYRAMZA be formulated with polysorbate 20 instead of polysorbate 80?

Potentially, but the change would require formulation development and comparability evidence. Polysorbate 20 and polysorbate 80 have different fatty-acid compositions and degradation behavior.

Is CYRAMZA a candidate for a lyophilized formulation?

Yes, technically. A lyophilized presentation could improve certain stability attributes, but it would add cycle-development, reconstitution, packaging, and administration complexity. The commercial case depends on whether the stability benefit outweighs those costs.

Can a biosimilar use different excipients from CYRAMZA?

Yes. A biosimilar does not generally need to duplicate the reference product’s complete excipient system, provided the product meets the applicable similarity, quality, safety, and efficacy requirements.

Does CYRAMZA have an interchangeable biosimilar?

An interchangeable biosimilar requires a specific FDA designation. Approval of a biosimilar alone does not establish interchangeability. The FDA Purple Book is the controlling source for current designation status.[4]

Are CYRAMZA excipients likely to be patentable by themselves?

Individual excipients such as sodium chloride, glycine, histidine, and polysorbate 80 are established materials. Patent value is more likely to arise from a defined combination, concentration range, pH range, stability result, manufacturing process, or delivery presentation.

References

1. U.S. Food and Drug Administration. (2024). CYRAMZA (ramucirumab) injection, prescribing information.
2. U.S. Food and Drug Administration. (2014, April 21). FDA approves CYRAMZA for advanced stomach cancer.
3. U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products.
4. U.S. Congress. (2010). Patient Protection and Affordable Care Act, Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.